1. Infliximab and risk of serious infection in patients with psoriasis. (1st February 2019) Authors: Yiu, Z.Z.N.; Ashcroft, D.M.; Evans, I.; McElhone, K.; Lunt, M.; Smith, C.H.; Walton, S.; Murphy, R.; Reynolds, N.J.; Ormerod, A.D.; Griffiths, C.E.M.; Warren, R.B. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Infliximab and risk of serious infection in patients with psoriasis. (4th February 2019) Authors: Yiu, Z.Z.N.; Ashcroft, D.M.; Evans, I.; McElhone, K.; Lunt, M.; Smith, C.H.; Walton, S.; Murphy, R.; Reynolds, N.J.; Ormerod, A.D.; Griffiths, C.E.M.; Warren, R.B. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (21st October 2018) Authors: Yiu, Z.Z.N.; Ashcroft, D.M.; Evans, I.; McElhone, K.; Lunt, M.; Smith, C.H.; Walton, S.; Murphy, R.; Reynolds, N.J.; Ormerod, A.D.; Griffiths, C.E.M.; Warren, R.B. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (1st February 2019) Authors: Yiu, Z.Z.N.; Ashcroft, D.M.; Evans, I.; McElhone, K.; Lunt, M.; Smith, C.H.; Walton, S.; Murphy, R.; Reynolds, N.J.; Ormerod, A.D.; Griffiths, C.E.M.; Warren, R.B. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (1st May 2017) Authors: Iskandar, I.Y.K.; Ashcroft, D.M.; Warren, R.B.; Evans, I.; McElhone, K.; Owen, C.M.; Burden, A.D.; Smith, C.H.; Reynolds, N.J.; Griffiths, C.E.M. Journal: British journal of dermatology Issue: Volume 176:Number 5(2017) Page Start: 1297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (20th March 2017) Authors: Iskandar, I.Y.K.; Ashcroft, D.M.; Warren, R.B.; Evans, I.; McElhone, K.; Owen, C.M.; Burden, A.D.; Smith, C.H.; Reynolds, N.J.; Griffiths, C.E.M. Journal: British journal of dermatology Issue: Volume 176:Number 5(2017) Page Start: 1297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). (10th September 2019) Authors: Mahil, S.K.; Wilson, N.; Dand, N.; Reynolds, N.J.; Griffiths, C.E.M.; Emsley, R.; Marsden, A.; Evans, I.; Warren, R.B.; Stocken, D.; Barker, J.N.; Burden, A.D.; Smith, C.H. Journal: British journal of dermatology Issue: Volume 182:Number 5(2020) Page Start: 1158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). (1st May 2020) Authors: Mahil, S.K.; Wilson, N.; Dand, N.; Reynolds, N.J.; Griffiths, C.E.M.; Emsley, R.; Marsden, A.; Evans, I.; Warren, R.B.; Stocken, D.; Barker, J.N.; Burden, A.D.; Smith, C.H. Journal: British journal of dermatology Issue: Volume 182:Number 5(2020) Page Start: 1158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 英夫利昔单抗用于银屑病患者及其引起严重感染的 风险. (1st February 2019) Authors: Yiu, Z.Z.N.; Ashcroft, D.M.; Evans, I.; McElhone, K.; Lunt, M.; Smith, C.H.; Walton, S.; Murphy, R.; Reynolds, N.J.; Ormerod, A.D.; Griffiths, C.E.M.; Warren, R.B. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: e59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 英夫利昔单抗用于银屑病患者及其引起严重感染的 风险. (4th February 2019) Authors: Yiu, Z.Z.N.; Ashcroft, D.M.; Evans, I.; McElhone, K.; Lunt, M.; Smith, C.H.; Walton, S.; Murphy, R.; Reynolds, N.J.; Ormerod, A.D.; Griffiths, C.E.M.; Warren, R.B. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: e59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗